In fact, published studies utilizing knock down approaches [24], blockage of PELP1 downstream signaling utilizing a KDM1A inhibitor [24], and reducing PELP1 expression using a CDK inhibitor Roscovitine [25], demonstrate the benefit of targeting PELP1 in reducing cancer progression. Here, KDM1A is linked to cancer.